Clinical experience with planning, quality assurance, and delivery of burst-mode modulated arc therapy.
"Burst-mode" modulated arc therapy (hereafter referred to as "mARC") is a form of volumetric-modulated arc therapy characterized by variable gantry rotation speed, static MLCs while the radiation beam is on, and MLC repositioning while the beam is off. We present our clinical experience with the planning techniques and plan quality assurance measurements of mARC delivery. Clinical mARC plans for five representative cases (prostate, low-dose-rate brain, brain with partial-arc vertex fields, pancreas, and liver SBRT) were generated using a Monte Carlo-based treatment planning system. A conventional-dose-rate flat 6 MV and a high-dose-rate non-flat 7 MV beam are available for planning and delivery. mARC plans for intact-prostate cases can typically be created using one 360° arc, and treatment times per fraction seldom exceed 6 min using the flat beam; using the nonflat beam results in slightly higher MU per fraction, but also in delivery times less than 4 min and with reduced mean dose to distal organs at risk. mARC also has utility in low-dose-rate brain irradiation; mARC fields can be designed which deliver a uniform 20 cGy dose to the PTV in approximately 3-minute intervals, making it a viable alternative to conventional 3D CRT. For brain cases using noncoplanar arcs, delivery time is approximately six min using the nonflat beam. For pancreas cases using the nonflat beam, two overlapping 360° arcs are required, and delivery times are approximately 10 min. For liver SBRT, the time to deliver 800 cGy per frac-tion is at least 12 min. Plan QA measurements indicate that the mARC delivery is consistent with the plan calculation for all cases. mARC has been incorporated into routine practice within our clinic; currently, on average approximately 15 patients per day are treated using mARC; and with the exception of LDR brain cases, all are treated using the nonflat beam.
Medical College of Wisconsin. kkainz@mcw.edu.
Kristofer
K
Kainz
Douglas
D
Prah
Ergun
E
Ahunbay
X Allen
XA
Li
D001932:Brain Neoplasms / Q000532:radiotherapy*; D006801:Humans; D008113:Liver Neoplasms / Q000532:radiotherapy*; D008297:Male; D009010:Monte Carlo Method; D010190:Pancreatic Neoplasms / Q000532:radiotherapy*; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011785:Quality Assurance, Health Care / Q000592:standards*; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods*; D050397:Radiotherapy, Intensity-Modulated / Q000592:standards*
Med Phys. 2008 Jan;35(1):310-7
18293586
J Clin Oncol. 2008 Feb 1;26(4):657-64
18172187
Med Phys. 1993 Nov-Dec;20(6):1709-19
8309444
Int J Radiat Oncol Biol Phys. 1990 Dec;19(6):1397-403
2262364
Phys Med Biol. 1995 Sep;40(9):1435-49
8532757
Med Phys. 2009 Jun;36(6):2328-39
19610322
Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1262-71
17967316
Radiat Oncol. 2014 Nov 26;9:250
25424536
Med Phys. 2011 Sep;38(9):5104-18
21978056
Med Phys. 2013 Jan;40(1):011704
23298074
Ann Surg Oncol. 2011 Apr;18(4):1081-7
21046264
Br J Radiol. 2007 Jan;80(949):32-7
16945935
Phys Med Biol. 2011 Apr 7;56(7):1931-46
21364260
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e447-53
21645977
Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1310-8
18374221
J Appl Clin Med Phys. 2015 Mar 08;16(2):5351
26103202